Related content

Pathological gambling in two patients on dopamine replacement therapy for Parkinson’s disease

By Avanzi M.   Uber E.   Bonfà F.  

Neurological Sciences, Vol. 25, Iss. 2, 2004-06 ,pp. : 98-101

Springer Publishing Company

Access to resources Recommend Favorite

A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson’s disease – a subjective view

By Horowski R.  

Journal of Neural Transmission, Vol. 114, Iss. 1, 2007-01 ,pp. : 127-134

Springer Publishing Company

Access to resources Recommend Favorite

Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson’s disease

By Shiraishi M.   Kamo T.   Hotta M.   Nemoto S.   Oshima J.   Sugihara H.   Yasaki S.   Kawakami M.   Takahashi Y.   Shimojo S.  

Journal of Neural Transmission, Vol. 111, Iss. 6, 2004-06 ,pp. : 725-732

Springer Publishing Company

Access to resources Recommend Favorite

Initiation of symptomatic therapy in Parkinson's disease: dopamine agonists versus levodopa

By Lev Nirit   Djaldetti Ruth   Melamed Eldad  

Journal of Neurology, Vol. 254, Iss. 5, 2007-09 ,pp. : 19-26

Springer Publishing Company

Access to resources Recommend Favorite

Therapy for dyskinesias in Parkinson’s disease patients

By Stefani Alessandro   Pierantozzi Mariangela   Koch Giacomo   Galati Salvatore   Stanzione Paolo  

Future Neurology, Vol. 5, Iss. 2, 2010-03 ,pp. : 277-299

Future Medicine

Access to resources Recommend Favorite